Market Cap (In USD)
8.49 Million
Revenue (In USD)
-
Net Income (In USD)
-3.61 Million
Avg. Volume
5603.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.03-0.07
- PE
- -0.75
- EPS
- -0.04
- Beta Value
- 0.825
- ISIN
- CA76128M1086
- CUSIP
- -
- CIK
- -
- Shares
- 283147000.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Donald J. McCaffrey
- Employee Count
- -
- Website
- https://www.resverlogix.com
- Ipo Date
- 2009-02-13
- Details
- Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.
More Stocks
-
VTAS
-
ATAMAtam Valves Limited
ATAM
-
FNNCFFinancial 15 Split Corp.
FNNCF
-
ATAMAtam Valves Limited
ATAM
-
002392
-
HPMCFAfrica Energy Corp.
HPMCF
-
88E
-
ADM